Ligand Pharmaceuticals Inc. Earns Milestone Payment Triggered By EU Approval Of Merck & Co.’s Captisol-Enabled NOXAFIL® (posaconazole) Concentrate For Solution For Infusion

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that Merck, known as MSD outside the United States and Canada, has received approval for NOXAFIL® (posaconazole) 300 mg Concentrate for Solution for Infusion from the European Medicines Agency (EMA). Ligand earns a $550,000 milestone payment as a result of the approval. Ligand will sell Captisol to Merck for the product marketed in Europe under an existing commercial supply agreement.

Help employers find you! Check out all the jobs and post your resume.